16 
ccmposed of 20 nenbers, with two non-af filiated members, non-af filiated 
representation would be 10 percent or half of the non-af filiated com- 
position mandated under the current Guidelines. He said the failure to 
maintain this requiresnent troubled him, Cr. Mason pointed out that a 
f ive-membered IBC would have at least 40 percent of its membership non- 
affiliated. Cr. McKinney said he believed that the institution, v*iich 
appoints members to the IBC, will respond to the intent of the Guidelines 
and appoint IBCs of an appropriate ccmpoeition. 
Moving to the next section. Dr. Nightingale called the attention of the 
RAC to Section rv-B-2-f. Section IV-B-2-f reads: 
"Institutions are encouraged to open IBC meetings to the public, 
whenever possible, consistent with protection of privacy and 
proprietary interests." 
Dr. Nightingale said no modifications were suggested for this section but 
noted that one member of the working group, Ms. King, felt the issue of 
open meetings should be evaluated at some point in the future and that 
open meetings probably should eventually be required. 
Dr. Nightingale fin^dly noted the addition of proposed language to Section 
rv-D-4. The proposed language reads: 
"Note: Other Federal agencies v4iich have adopted the NIH 
Guidelines may have the authority to terminate funding to 
their grantees should these grantees not conply with the NIH 
Guidelines." 
She felt this statement is not sufficient and that the section should 
be expanded to include a description of the Federal Interagency Advisory 
Committee on Recombinant CNA Research and of its membership. Dr, Goldstein 
felt that some description of the Interagency Comnittee would be desirable. 
In particular, a stataw?nt that its members have agreed to abide by the 
NIH Guidelines should be included. Dr. Gottesman suggested that an Appendix, 
describing the Interagency Committee, its agency members, and a statement 
that these agencies have agreed to abide by the Guidelines, be added 
to the Guidelines. References would be made to this new Appendix at 
(1) Section IV-C-l-a-{4) which describes the Director's responsibility 
for maintaining this committee, and (2) mder Section IV-D-4 in place of 
the "Note". Cr. Ahmed suggested the proposed Appendix should also describe 
how the Interagency Committee was formed, who it reports to, and what 
responsibilities member agencies have assumed with respect to the NIH 
Guidelines. Dr. Ahmed agreed to accept this amendment, as did Dr. Bems, 
Dr. Goldstein said he still had concerns on the potential use of recom- 
binant DNA technology for biological warfare. He noted that the Department 
of Defense (DOD) is a member of the Interagency Committee. He said that 
earlier in the meeting RAC heard of classified research conducted by DOD, 
However, several questions on this research had not been answered to 
Dr. Goldstein's satisfaction by the DOD representative. Dr. McCullough 
[4751 
